1267 related articles for article (PubMed ID: 31590682)
41. Recurrent
Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
[TBL] [Abstract][Full Text] [Related]
42. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
[TBL] [Abstract][Full Text] [Related]
43. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.
Aguilar A; Zheng K; Xu T; Xu S; Huang L; Fernandez-Salas E; Liu L; Bernard D; Harvey KP; Foster C; McEachern D; Stuckey J; Chinnaswamy K; Delproposto J; Kampf JW; Wang S
J Med Chem; 2019 Jul; 62(13):6015-6034. PubMed ID: 31244110
[TBL] [Abstract][Full Text] [Related]
44. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
45. Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML).
Stubbs MC; Krivtsov AV
Curr Protoc Pharmacol; 2017 Sep; 78():14.42.1-14.42.19. PubMed ID: 28892146
[TBL] [Abstract][Full Text] [Related]
46. Integrated transcriptomic and epigenetic data analysis identifiesaberrant expression of genes in acute myeloid leukemia with MLL‑AF9 translocation.
Wang F; Li Z; Wang G; Tian X; Zhou J; Yu W; Fan Z; Dong L; Lu J; Xu J; Zhang W; Liang A
Mol Med Rep; 2020 Feb; 21(2):883-893. PubMed ID: 31789407
[TBL] [Abstract][Full Text] [Related]
47. NUP98-MLL fusion in human acute myeloblastic leukemia.
Kaltenbach S; Soler G; Barin C; Gervais C; Bernard OA; Penard-Lacronique V; Romana SP
Blood; 2010 Sep; 116(13):2332-5. PubMed ID: 20558618
[TBL] [Abstract][Full Text] [Related]
48. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
Zhang X; Zheng X; Yang H; Yan J; Fu X; Wei R; Xu X; Zhang Z; Yu A; Zhou K; Ding J; Geng M; Huang X
Cancer Lett; 2018 Sep; 431():150-160. PubMed ID: 29857126
[TBL] [Abstract][Full Text] [Related]
49. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
[TBL] [Abstract][Full Text] [Related]
50. Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-κB/COX-2 signaling pathways.
Tang YL; Sun X; Huang LB; Liu XJ; Qin G; Wang LN; Zhang XL; Ke ZY; Luo JS; Liang C; Peng CJ; Tang WY; Li Y; Huang W; Luo XQ; Deng W
Cancer Lett; 2019 Feb; 443():167-178. PubMed ID: 30550850
[TBL] [Abstract][Full Text] [Related]
51. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
Grembecka J; Belcher AM; Hartley T; Cierpicki T
J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
[TBL] [Abstract][Full Text] [Related]
52. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
53. Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong
Xu S; Aguilar A; Huang L; Xu T; Zheng K; McEachern D; Przybranowski S; Foster C; Zawacki K; Liu Z; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2020 May; 63(9):4997-5010. PubMed ID: 32338903
[TBL] [Abstract][Full Text] [Related]
54. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
[TBL] [Abstract][Full Text] [Related]
55. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
56. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
57. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
[TBL] [Abstract][Full Text] [Related]
58. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
[TBL] [Abstract][Full Text] [Related]
59. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia.
Itskovich SS; Gurunathan A; Clark J; Burwinkel M; Wunderlich M; Berger MR; Kulkarni A; Chetal K; Venkatasubramanian M; Salomonis N; Kumar AR; Lee LH
Nat Commun; 2020 May; 11(1):2369. PubMed ID: 32398749
[TBL] [Abstract][Full Text] [Related]
60. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
